ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ABBV-142

A development code.

Its studies are mostly in Idiopathic Pulmonary Fibrosis, led by AbbVie.

Furthest: phase 2, since Nov 14, 20252 company-led studies, 1 open or runningNext primary completion: Sep 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie21 open or runningphase 2since Nov 14, 2025Jan 9, 2025Sep 2029phase 2 · NCT07230288

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 9, 2025First study: phase 1 study in Healthy VolunteerFirst studyNCT06774313 · 73 enrolled · United States
  2. Nov 14, 2025Phase 2 study in Idiopathic Pulmonary FibrosisNCT07230288 · 165 planned · United States, Australia, Bulgaria and more

Ahead

  1. Sep 2029Primary completion: phase 2 study in Idiopathic Pulmonary FibrosisNCT07230288

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07230288Idiopathic Pulmonary Fibrosis · United States, Australia, Bulgaria and more2RecruitingSep 2029165
NCT06774313Healthy Volunteer · United States1CompletedApr 8, 202673

How it is read

Names in the registry

  • “ABBV-142”, 3 entries

Codes read as this program: ABBV142.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.